AstraZeneca and Pfizer CEOs support China's biopharmaceutical expansion despite US decoupling, investing in innovation and manufacturing.

AstraZeneca and Pfizer CEOs pledge support for China's biopharmaceutical expansion despite US efforts to decouple supply chains, viewing China as vital for innovation and manufacturing. AstraZeneca has invested $1B in Chinese manufacturing facilities and global licensing deals worth $6B with local biotech firms. Pfizer sees promising prospects in cutting-edge drug development in China.